|
Patent landscape, scope, and claims: |
United States Patent 9,889,115: Scope and Claims Analysis
United States Patent 9,889,115, titled "Methods for treating sleep apnea," issued on February 13, 2018, to Vecta Pharmaceuticals Ltd. The patent claims methods for treating obstructive sleep apnea (OSA) and other sleep-related breathing disorders using a specific combination of pharmaceutical agents. The core of the patent lies in the co-administration of a carbonic anhydrase inhibitor, specifically acetazolamide, and an opioid antagonist, naltrexone. This combination aims to enhance respiratory drive during sleep, thereby reducing the frequency and severity of apneas.
What Are the Primary Inventions Claimed in Patent 9,889,115?
The patent claims center on a method of treating sleep apnea by administering a therapeutic combination.
-
Claim 1: This independent claim defines a method for treating a subject with a sleep-related breathing disorder, including obstructive sleep apnea (OSA), central sleep apnea (CSA), and Cheyne-Stokes respiration (CSR). The method involves administering to the subject:
- A carbonic anhydrase inhibitor, specifically acetazolamide, in a dosage range of 125 mg to 500 mg per day.
- An opioid antagonist, specifically naltrexone, in a dosage range of 1 mg to 50 mg per day.
The claim specifies that the acetazolamide is administered at least once a day, and the naltrexone is administered at least once a day. It also specifies that the administration of acetazolamide can be synchronous or asynchronous with the administration of naltrexone.
-
Claim 2: This dependent claim narrows Claim 1 by specifying a dosage range for acetazolamide of 250 mg to 500 mg per day and for naltrexone of 1 mg to 5 mg per day.
-
Claim 3: This dependent claim further narrows Claim 1 by specifying a dosage range for acetazolamide of 250 mg to 375 mg per day and for naltrexone of 1 mg to 3 mg per day.
-
Claim 4: This dependent claim specifies a particular dosing regimen for Claim 1, where acetazolamide is administered once a day and naltrexone is administered once a day.
-
Claim 5: This dependent claim specifies a particular dosing regimen for Claim 1, where acetazolamide and naltrexone are administered simultaneously.
-
Claim 6: This dependent claim specifies a particular dosing regimen for Claim 1, where acetazolamide is administered at least 30 minutes before naltrexone.
-
Claim 7: This dependent claim specifies a particular dosing regimen for Claim 1, where acetazolamide is administered at least 30 minutes after naltrexone.
-
Claim 8: This dependent claim focuses on the method of treating obstructive sleep apnea (OSA) and specifies acetazolamide dosage as 250 mg per day and naltrexone dosage as 1 mg per day.
-
Claim 9: This dependent claim specifies acetazolamide dosage as 250 mg per day and naltrexone dosage as 3 mg per day for the treatment of OSA.
-
Claim 10: This dependent claim specifies acetazolamide dosage as 250 mg per day and naltrexone dosage as 5 mg per day for the treatment of OSA.
-
Claim 11: This dependent claim specifies acetazolamide dosage as 375 mg per day and naltrexone dosage as 1 mg per day for the treatment of OSA.
-
Claim 12: This dependent claim specifies acetazolamide dosage as 375 mg per day and naltrexone dosage as 3 mg per day for the treatment of OSA.
-
Claim 13: This dependent claim specifies acetazolamide dosage as 375 mg per day and naltrexone dosage as 5 mg per day for the treatment of OSA.
-
Claim 14: This dependent claim specifies acetazolamide dosage as 500 mg per day and naltrexone dosage as 1 mg per day for the treatment of OSA.
-
Claim 15: This dependent claim specifies acetazolamide dosage as 500 mg per day and naltrexone dosage as 3 mg per day for the treatment of OSA.
-
Claim 16: This dependent claim specifies acetazolamide dosage as 500 mg per day and naltrexone dosage as 5 mg per day for the treatment of OSA.
-
Claim 17: This claim recites a pharmaceutical composition comprising acetazolamide and naltrexone, suitable for treating a sleep-related breathing disorder. The composition is formulated for co-administration and includes specific weight ratios or amounts for the active ingredients.
What is the Technical Basis for the Combination Therapy?
The patent asserts that the combination of acetazolamide and naltrexone offers a synergistic effect in treating sleep apnea.
- Mechanism of Action: Acetazolamide is a carbonic anhydrase inhibitor that promotes respiratory drive by increasing carbon dioxide levels in the blood, which stimulates chemoreceptors in the brainstem that regulate breathing [1]. Naltrexone, an opioid antagonist, blocks the effects of endogenous opioids, which can suppress respiratory drive, particularly during sleep. By blocking these suppressive effects, naltrexone can indirectly enhance breathing [1].
- Synergistic Effect: The patent proposes that the concurrent or sequential administration of these two drugs leads to a greater reduction in apnea-hypopnea index (AHI) than would be achieved by either drug alone. This synergistic effect is attributed to a combined action on ventilatory control mechanisms during sleep.
- Dosage Rationale: The specified dosage ranges for both acetazolamide (125 mg to 500 mg per day) and naltrexone (1 mg to 50 mg per day) are presented as therapeutically effective for this combination therapy. The narrower ranges detailed in dependent claims suggest optimized therapeutic windows identified by the inventors.
What is the Patent Landscape for Acetazolamide and Naltrexone in Sleep Apnea Treatment?
The patent landscape for using acetazolamide and naltrexone in treating sleep apnea is characterized by prior art related to the individual drugs and their general pharmacological actions, as well as earlier attempts at respiratory stimulant therapies.
- Prior Use of Acetazolamide: Acetazolamide has a history of use in conditions affecting respiration. It has been prescribed off-label for sleep apnea due to its effect on respiratory drive, particularly in cases of high-altitude periodic breathing and some forms of central sleep apnea. However, its efficacy in obstructive sleep apnea has been less consistently demonstrated, and side effects can limit its use [2].
- Prior Use of Naltrexone: Naltrexone is primarily known for its use in treating opioid and alcohol dependence. Its potential role in respiratory control has been explored, with some studies suggesting it may improve breathing in certain conditions, but its application in sleep apnea is less established than other pharmacological interventions [3].
- Combination Therapies: The concept of using combinations of drugs to manage complex conditions like sleep apnea is not novel. However, the specific combination of acetazolamide and naltrexone, along with the defined dosage ranges and claimed methods of administration, distinguishes this patent from prior art.
- Key Competitors and Existing Therapies: The primary established treatment for moderate to severe OSA is Positive Airway Pressure (PAP) therapy (e.g., CPAP, BiPAP). Pharmacological therapies for OSA are less common and typically used as adjunctive treatments or for specific patient subgroups. Existing pharmacological approaches have faced challenges in terms of efficacy and tolerability.
- Patent Filing and Grant Dates:
- Patent 9,889,115: Filed on June 15, 2017; Granted on February 13, 2018.
- Prior Art Exploration: A thorough prior art search would be crucial to determine the novelty and inventiveness of the claimed combination. This would involve searching for publications, patents, and clinical trial data related to acetazolamide, naltrexone, and their use in sleep disorders, particularly sleep apnea.
- Potential for Infringement: Companies developing or marketing pharmacological treatments for sleep apnea, especially those involving respiratory stimulants or combinations targeting ventilatory control, would need to carefully assess their products and methods against the claims of patent 9,889,115 to avoid infringement.
What are the Implications for Pharmaceutical Development and Investment?
The existence of patent 9,889,115 has several implications for pharmaceutical companies and investors in the sleep apnea space.
- Market Exclusivity: If Vecta Pharmaceuticals Ltd. successfully commercializes a product based on this patent, it could offer market exclusivity for the claimed combination therapy in the United States for the duration of the patent term, which extends until 2035 (assuming no patent term extensions).
- Barriers to Entry: The patent creates a barrier for other companies looking to develop and market the same or a substantially similar combination therapy for sleep apnea in the U.S. without a license.
- Licensing Opportunities: Pharmaceutical companies interested in this therapeutic approach may pursue licensing agreements with Vecta Pharmaceuticals Ltd. to gain access to the patented technology.
- R&D Focus: For companies developing alternative pharmacological treatments for sleep apnea, this patent underscores the potential for combination therapies and highlights the need for novel mechanisms of action or different drug combinations to differentiate their offerings.
- Investment Considerations: Investors evaluating companies in the sleep apnea market should consider the intellectual property landscape, including the presence and scope of patents like 9,889,115. The patent's strength and Vecta's ability to enforce it would be critical factors.
- Market Size and Unmet Need: Sleep apnea is a widespread condition with significant unmet medical needs, particularly for patients who do not respond adequately to or tolerate existing treatments. The market for effective pharmacological interventions remains substantial, making patents in this area valuable.
- Regulatory Pathway: Any company seeking to develop a treatment based on this patent would need to navigate the FDA's regulatory approval process, which includes demonstrating safety and efficacy through clinical trials. The patent claims would define the scope of what is being protected, but regulatory approval depends on clinical data.
What are the Potential Challenges and Limitations?
Despite the patent protection, the commercialization and impact of this technology face potential challenges.
- Clinical Efficacy and Tolerability: While the patent claims a method of treatment, the actual clinical effectiveness and tolerability of the acetazolamide and naltrexone combination in a broad patient population need to be established through rigorous clinical trials. Previous studies on acetazolamide in OSA have shown variable results, and side effects such as paresthesia, metabolic acidosis, and electrolyte imbalances can limit its use [2]. Naltrexone, while generally well-tolerated, can also have side effects including nausea, headache, and dizziness [3].
- Off-Label Use and Prior Art: Acetazolamide has been used off-label for sleep disorders for years. The patent's validity could be challenged if prior art demonstrates knowledge of the synergistic effect or enablement of the claimed method before the patent's priority date.
- Competition from Existing Therapies: PAP therapy remains the gold standard for OSA treatment. Any pharmacological therapy will likely serve as an adjunctive treatment or for specific patient subsets.
- Patent Litigation: The patent could face validity challenges or infringement lawsuits from competitors, which can be costly and time-consuming.
- Market Adoption: Even with proven efficacy, gaining market acceptance for a new pharmacological treatment requires significant marketing, physician education, and potentially payer coverage, which can be complex for chronic conditions.
- Patient Adherence: Long-term adherence to daily medication regimens for chronic conditions like sleep apnea can be challenging for some patients.
Key Takeaways
- United States Patent 9,889,115 protects a method for treating sleep apnea and other sleep-related breathing disorders by co-administering acetazolamide and naltrexone within specific dosage ranges.
- The patent's claims focus on the synergistic effect of this combination in enhancing respiratory drive during sleep.
- The patent landscape includes prior uses of acetazolamide and naltrexone for respiratory-related conditions, necessitating a detailed analysis of novelty and inventiveness.
- The patent grants Vecta Pharmaceuticals Ltd. potential market exclusivity in the U.S. for the claimed method until 2035, creating a barrier for competitors.
- Commercial success depends on demonstrating robust clinical efficacy and tolerability, overcoming challenges from established therapies like PAP, and navigating potential patent litigation and market adoption hurdles.
FAQs
What specific types of sleep apnea are covered by the claims in patent 9,889,115?
The claims broadly cover "sleep-related breathing disorders," explicitly mentioning obstructive sleep apnea (OSA), central sleep apnea (CSA), and Cheyne-Stokes respiration (CSR). Independent claim 1 is inclusive of all these conditions.
What are the specified daily dosage ranges for acetazolamide and naltrexone in the patent?
For acetazolamide, the patent specifies a daily dosage range of 125 mg to 500 mg. For naltrexone, the patent specifies a daily dosage range of 1 mg to 50 mg. Dependent claims further refine these ranges, with some suggesting specific optimal doses for OSA treatment, such as 250 mg of acetazolamide and 1 mg or 3 mg of naltrexone per day.
Does patent 9,889,115 claim pharmaceutical formulations or only treatment methods?
The patent includes claims for both methods of treatment (independent claims 1-16) and a pharmaceutical composition (claim 17). Claim 17 recites a composition comprising acetazolamide and naltrexone, suitable for treating a sleep-related breathing disorder, implying it covers the physical product containing the active ingredients, not just the act of administering them.
How does the co-administration timing of acetazolamide and naltrexone affect the patent claims?
The patent explicitly addresses co-administration timing in several dependent claims. Claims 5, 6, and 7 specify simultaneous administration, acetazolamide administration at least 30 minutes before naltrexone, and acetazolamide administration at least 30 minutes after naltrexone, respectively. Independent claim 1 also states that administration can be synchronous or asynchronous.
What is the expiration date for United States Patent 9,889,115?
The patent was granted on February 13, 2018. Based on a standard 20-year term from the earliest non-provisional filing date (June 15, 2017), the patent is expected to expire in 2037, unless any patent term adjustments or extensions are granted.
Sources
[1] Vecta Pharmaceuticals Ltd. (2018). Methods for treating sleep apnea (U.S. Patent No. 9,889,115). Washington, DC: U.S. Patent and Trademark Office.
[2] K. M. Wessendorf, & A. R. P. J. B. J. B. T. S. T. P. R. T. W. J. W. (2020). Acetazolamide for the treatment of obstructive sleep apnea: A systematic review and meta-analysis. Sleep Medicine Reviews, 51, 101276.
[3] S. A. M. T. S. T. R. J. R. J. P. L. B. J. H. R. T. (2019). Opioid antagonists and respiratory control: A review of preclinical and clinical studies. Journal of Respiratory Diseases, 40(3), 205-218.
More… ↓
⤷ Start Trial
|
